These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 34948368)

  • 1. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.
    Wu TN; Chen HM; Shyur LF
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
    Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
    Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.
    Adinew GM; Taka E; Mochona B; Badisa RB; Mazzio EA; Elhag R; Soliman KFA
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer.
    Munkácsy G; Santarpia L; Győrffy B
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
    Malla RR; Vasudevaraju P; Vempati RK; Rakshmitha M; Merchant N; Nagaraju GP
    Cancer; 2022 Mar; 128(6):1171-1183. PubMed ID: 34990009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
    Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
    J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.
    Qattan A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
    Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.
    Kajihara N; Kobayashi T; Otsuka R; Nio-Kobayashi J; Oshino T; Takahashi M; Imanishi S; Hashimoto A; Wada H; Seino KI
    Cancer Immunol Immunother; 2023 Apr; 72(4):851-864. PubMed ID: 36104597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.
    Zajac KK; Malla S; Babu RJ; Raman D; Tiwari AK
    Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1779. PubMed ID: 36632988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
    Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
    Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
    Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C
    J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.